Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Fabry Disease Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Fabry Disease Overview | 8 | 1 |
| Fabry Disease Therapeutics under Development by Companies | 9 | 2 |
| Fabry Disease Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Fabry Disease Products under Development by Companies | 14 | 1 |
| Fabry Disease Companies Involved in Therapeutics Development | 15 | 12 |
| Actelion Ltd | 15 | 1 |
| Alexion Pharmaceuticals Inc | 16 | 1 |
| Amicus Therapeutics, Inc. | 17 | 1 |
| Genzyme Corporation | 18 | 1 |
| Greenovation Biotech GmbH | 19 | 1 |
| ISU ABXIS Co.,Ltd. | 20 | 1 |
| JCR Pharmaceuticals Co., Ltd. | 21 | 1 |
| Neuraltus Pharmaceuticals, Inc. | 22 | 1 |
| Pharming Group N.V. | 23 | 1 |
| Protalix BioTherapeutics, Inc. | 24 | 1 |
| Sangamo BioSciences, Inc. | 25 | 1 |
| Shire Plc | 26 | 1 |
| Fabry Disease Therapeutics Assessment | 27 | 10 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Combination Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 27 |
| agalsidase alfa Drug Profile | 37 | 2 |
| agalsidase alfa Drug Profile | 39 | 1 |
| agalsidase beta biosimilar Drug Profile | 40 | 1 |
| AVR-02 Drug Profile | 41 | 1 |
| Enzyme Replacement Therapy + migalastat hydrochloride Biobetter Drug Profile | 42 | 1 |
| ibiglustat Drug Profile | 43 | 2 |
| lucerastat Drug Profile | 45 | 1 |
| migalastat hydrochloride Drug Profile | 46 | 8 |
| MOSS-AGAL Drug Profile | 54 | 2 |
| NP-003 Drug Profile | 56 | 1 |
| PRX-102 Drug Profile | 57 | 4 |
| Recombinant Alpha-Galactosidase A Replacement for Fabry Disease Drug Profile | 61 | 1 |
| Recombinant Enzymes for Pompe, Fabry and Hunter Diseases Drug Profile | 62 | 1 |
| SBLSD-4 Drug Profile | 63 | 1 |
| Fabry Disease Dormant Projects | 64 | 1 |
| Fabry Disease Discontinued Products | 65 | 1 |
| Fabry Disease Product Development Milestones | 66 | 14 |
| Featured News &Press Releases | 66 | 1 |
| Aug 10, 2016: New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease | 66 | 1 |
| Aug 10, 2016: Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease | 67 | 1 |
| Aug 03, 2016: Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17 | 68 | 1 |
| Aug 02, 2016: Almac Group s Integrated Development to Commercialisation Services Support Amicus Therapeutics First Commercial Orphan Drug Product | 69 | 1 |
| Jun 06, 2016: Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings | 69 | 1 |
| May 31, 2016: Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union | 70 | 2 |
| Apr 01, 2016: Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union | 72 | 1 |
| Apr 01, 2016: First oral treatment for Fabry disease recommended for approval in the EU | 73 | 1 |
| Mar 22, 2016: Amicus Therapeutics Announces Expanded Access Program for Migalastat | 74 | 1 |
| Mar 03, 2016: Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium 2016 | 74 | 1 |
| Mar 01, 2016: Amicus Therapeutics Highlights New Phase 3 Fabry Data at WORLDSymposium 2016 | 75 | 1 |
| Feb 22, 2016: Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium 2016 | 76 | 1 |
| Feb 10, 2016: Amicus Therapeutics Announces Presentations on Migalastat at 12th Annual WORLDSymposium 2016 | 76 | 1 |
| Jan 11, 2016: Amicus Therapeutics Provides Update On Migalastat for Fabry Disease | 77 | 1 |
| Nov 16, 2015: Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA | 78 | 2 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |